255 related articles for article (PubMed ID: 22025154)
1. Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma.
Juergens H; Daw NC; Geoerger B; Ferrari S; Villarroel M; Aerts I; Whelan J; Dirksen U; Hixon ML; Yin D; Wang T; Green S; Paccagnella L; Gualberto A
J Clin Oncol; 2011 Dec; 29(34):4534-40. PubMed ID: 22025154
[TBL] [Abstract][Full Text] [Related]
2. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study.
Olmos D; Postel-Vinay S; Molife LR; Okuno SH; Schuetze SM; Paccagnella ML; Batzel GN; Yin D; Pritchard-Jones K; Judson I; Worden FP; Gualberto A; Scurr M; de Bono JS; Haluska P
Lancet Oncol; 2010 Feb; 11(2):129-35. PubMed ID: 20036194
[TBL] [Abstract][Full Text] [Related]
3. A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study.
Pappo AS; Vassal G; Crowley JJ; Bolejack V; Hogendoorn PC; Chugh R; Ladanyi M; Grippo JF; Dall G; Staddon AP; Chawla SP; Maki RG; Araujo DM; Geoerger B; Ganjoo K; Marina N; Blay JY; Schuetze SM; Chow WA; Helman LJ
Cancer; 2014 Aug; 120(16):2448-56. PubMed ID: 24797726
[TBL] [Abstract][Full Text] [Related]
4. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study.
Pappo AS; Patel SR; Crowley J; Reinke DK; Kuenkele KP; Chawla SP; Toner GC; Maki RG; Meyers PA; Chugh R; Ganjoo KN; Schuetze SM; Juergens H; Leahy MG; Geoerger B; Benjamin RS; Helman LJ; Baker LH
J Clin Oncol; 2011 Dec; 29(34):4541-7. PubMed ID: 22025149
[TBL] [Abstract][Full Text] [Related]
5. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.
Asmane I; Watkin E; Alberti L; Duc A; Marec-Berard P; Ray-Coquard I; Cassier P; Decouvelaere AV; Ranchère D; Kurtz JE; Bergerat JP; Blay JY
Eur J Cancer; 2012 Nov; 48(16):3027-35. PubMed ID: 22682017
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma.
Anderson PM; Bielack SS; Gorlick RG; Skubitz K; Daw NC; Herzog CE; Monge OR; Lassaletta A; Boldrini E; Pápai Z; Rubino J; Pathiraja K; Hille DA; Ayers M; Yao SL; Nebozhyn M; Lu B; Mauro D
Pediatr Blood Cancer; 2016 Oct; 63(10):1761-70. PubMed ID: 27362300
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors.
Tap WD; Demetri G; Barnette P; Desai J; Kavan P; Tozer R; Benedetto PW; Friberg G; Deng H; McCaffery I; Leitch I; Badola S; Chang S; Zhu M; Tolcher A
J Clin Oncol; 2012 May; 30(15):1849-56. PubMed ID: 22508822
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group.
Malempati S; Weigel B; Ingle AM; Ahern CH; Carroll JM; Roberts CT; Reid JM; Schmechel S; Voss SD; Cho SY; Chen HX; Krailo MD; Adamson PC; Blaney SM
J Clin Oncol; 2012 Jan; 30(3):256-62. PubMed ID: 22184397
[TBL] [Abstract][Full Text] [Related]
9. Targeting of insulin-like growth factor type 1 receptor in Ewing sarcoma: unfulfilled promise or a promising beginning?
Ho AL; Schwartz GK
J Clin Oncol; 2011 Dec; 29(34):4581-3. PubMed ID: 22025158
[No Abstract] [Full Text] [Related]
10. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors.
Quek R; Wang Q; Morgan JA; Shapiro GI; Butrynski JE; Ramaiya N; Huftalen T; Jederlinic N; Manola J; Wagner AJ; Demetri GD; George S
Clin Cancer Res; 2011 Feb; 17(4):871-9. PubMed ID: 21177764
[TBL] [Abstract][Full Text] [Related]
11. Response to Early Treatment Evaluated with 18F-FDG PET and PERCIST 1.0 Predicts Survival in Patients with Ewing Sarcoma Family of Tumors Treated with a Monoclonal Antibody to the Insulinlike Growth Factor 1 Receptor.
Hyun O J; Luber BS; Leal JP; Wang H; Bolejack V; Schuetze SM; Schwartz LH; Helman LJ; Reinke D; Baker LH; Wahl RL
J Nucl Med; 2016 May; 57(5):735-40. PubMed ID: 26795289
[TBL] [Abstract][Full Text] [Related]
12. The strength of small: improved targeting of insulin-like growth factor-1 receptor (IGF-1R) with F(ab')₂-R1507 fragments in Ewing sarcomas.
Fleuren ED; Versleijen-Jonkers YM; Heskamp S; Roeffen MH; Bouwman WH; Molkenboer-Kuenen JD; van Laarhoven HW; Oyen WJ; Boerman OC; van der Graaf WT
Eur J Cancer; 2013 Sep; 49(13):2851-8. PubMed ID: 23664098
[TBL] [Abstract][Full Text] [Related]
13. Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial.
Becerra CR; Salazar R; Garcia-Carbonero R; Thomas AL; Vázquez-Mazón FJ; Cassidy J; Maughan T; Castillo MG; Iveson T; Yin D; Green S; Bergsland EK
Cancer Chemother Pharmacol; 2014 Apr; 73(4):695-702. PubMed ID: 24488322
[TBL] [Abstract][Full Text] [Related]
14. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma.
Haluska P; Worden F; Olmos D; Yin D; Schteingart D; Batzel GN; Paccagnella ML; de Bono JS; Gualberto A; Hammer GD
Cancer Chemother Pharmacol; 2010 Mar; 65(4):765-73. PubMed ID: 19649631
[TBL] [Abstract][Full Text] [Related]
15. An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours.
Schöffski P; Adkins D; Blay JY; Gil T; Elias AD; Rutkowski P; Pennock GK; Youssoufian H; Gelderblom H; Willey R; Grebennik DO
Eur J Cancer; 2013 Oct; 49(15):3219-28. PubMed ID: 23835252
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy.
Choy E; Butrynski JE; Harmon DC; Morgan JA; George S; Wagner AJ; D'Adamo D; Cote GM; Flamand Y; Benes CH; Haber DA; Baselga JM; Demetri GD
BMC Cancer; 2014 Nov; 14():813. PubMed ID: 25374341
[TBL] [Abstract][Full Text] [Related]
17. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.
Kurmasheva RT; Dudkin L; Billups C; Debelenko LV; Morton CL; Houghton PJ
Cancer Res; 2009 Oct; 69(19):7662-71. PubMed ID: 19789339
[TBL] [Abstract][Full Text] [Related]
18. Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma.
Scotlandi K; Manara MC; Hattinger CM; Benini S; Perdichizzi S; Pasello M; Bacci G; Zanella L; Bertoni F; Picci P; Serra M
Eur J Cancer; 2005 Jun; 41(9):1349-61. PubMed ID: 15913990
[TBL] [Abstract][Full Text] [Related]
19. The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study.
Molife LR; Fong PC; Paccagnella L; Reid AH; Shaw HM; Vidal L; Arkenau HT; Karavasilis V; Yap TA; Olmos D; Spicer J; Postel-Vinay S; Yin D; Lipton A; Demers L; Leitzel K; Gualberto A; de Bono JS
Br J Cancer; 2010 Jul; 103(3):332-9. PubMed ID: 20628389
[TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factor 1 receptor inhibitors: where do we come from? What are we? Where are we going?
Chmielowski B
Cancer; 2014 Aug; 120(16):2384-7. PubMed ID: 24797606
[No Abstract] [Full Text] [Related]
[Next] [New Search]
